Nuformix plc
("Nuformix" or the "Company" or the "Group")
Notice of Annual General Meeting ("AGM")
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the 2023 Notice of AGM has today been posted to its shareholders:
A full pdf version of the Notice of AGM will shortly be available for download from the Investor Information section on the Company's website www.nuformix.com.
The AGM will be held on 24 August 2023 at 10.00 am at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director |
Via IFC Advisory |
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
John Howes / Bob Pountney (Corporate Broking) |
+44 (0) 20 3650 3652 |
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.